Treatment outcomes of macrolide-susceptible Mycobacterium abscessus lung disease

Diagn Microbiol Infect Dis. 2018 Apr;90(4):293-295. doi: 10.1016/j.diagmicrobio.2017.12.008. Epub 2017 Dec 16.

Abstract

Mycobacterium abscessus lung disease is difficult to treat due to inducible resistance to macrolides. However, 15%-20% of isolates are macrolide susceptible. In 14 patients with macrolide-susceptible M. abscessus lung disease, all isolates had nonfunctional erm(41) gene, and sputum culture conversion rate was achieved in 93% (13/14) following antibiotic therapy.

Keywords: Drug resistance; Macrolides; Mycobacterium abscessus; Nontuberculous mycobacteria; Treatment.

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Female
  • Humans
  • Macrolides / pharmacology
  • Macrolides / therapeutic use*
  • Male
  • Methyltransferases / genetics
  • Middle Aged
  • Mutation
  • Mycobacterium Infections, Nontuberculous / drug therapy*
  • Mycobacterium Infections, Nontuberculous / microbiology
  • Mycobacterium abscessus / drug effects
  • Mycobacterium abscessus / genetics
  • Mycobacterium abscessus / isolation & purification*
  • Pneumonia, Bacterial / drug therapy*
  • Pneumonia, Bacterial / microbiology
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Macrolides
  • Methyltransferases
  • rRNA (adenosine-O-2'-)methyltransferase